| 39.6845 0.415 (1.06%) | 04-19 10:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 48.83  |
1-year : | 50.74 |
| Resists | First : | 41.8 |
Second : | 43.45 |
| Pivot price | 40.92 |
|||
| Supports | First : | 39.15 |
Second : | 32.57 |
| MAs | MA(5) : | 39.99 |
MA(20) : | 41.36 |
| MA(100) : | 39.96  |
MA(250) : | 37.29 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 4.5 |
D(3) : | 4.5 |
| RSI | RSI(14): 24.7 |
|||
| 52-week | High : | 43.84 | Low : | 33.33 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GSK ] has closed above bottom band by 5.6%. Bollinger Bands are 45.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 39.91 - 40.19 | 40.19 - 40.4 |
| Low: | 38.7 - 39.08 | 39.08 - 39.38 |
| Close: | 39.07 - 39.59 | 39.59 - 39.99 |
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Fri, 19 Apr 2024
GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve (OTCMKTS:GLAXF) - Seeking Alpha
Thu, 18 Apr 2024
GSK falls Thursday, underperforms market - MarketWatch
Thu, 18 Apr 2024
GSK June 21st Options Begin Trading - Nasdaq
Wed, 17 Apr 2024
GSK Executives Acquire Shares Post-Dividend - TipRanks.com - TipRanks
Wed, 17 Apr 2024
GSK Announces FDA Acceptance of New Meningococcal Jab BLA - Yahoo Finance
Wed, 17 Apr 2024
GSK says efficacy of its shingles vaccine remains high after years - Reuters
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,040 (M) |
| Shares Float | 3,910 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 14.4 (%) |
| Shares Short | 4,830 (K) |
| Shares Short P.Month | 4,760 (K) |
| EPS | 3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.28 |
| Profit Margin | 16.2 % |
| Operating Margin | 20.3 % |
| Return on Assets (ttm) | 8.8 % |
| Return on Equity (ttm) | 46.3 % |
| Qtrly Rev. Growth | 9.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 14.86 |
| EBITDA (p.s.) | 5.04 |
| Qtrly Earnings Growth | -76.6 % |
| Operating Cash Flow | 6,770 (M) |
| Levered Free Cash Flow | 3,560 (M) |
| PE Ratio | 13.09 |
| PEG Ratio | 2.1 |
| Price to Book value | 11.93 |
| Price to Sales | 2.64 |
| Price to Cash Flow | 11.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|